Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from human gastric juice with regenerative and cytoprotective effects reported across diverse tissues. Despite extensive preclinical study, the precise molecular mechanism underlying BPC-157's pleiotropic pro-repair effects remains incompletely understood. A key unresolved question is whether BPC-157 acts through extracellular receptor engagement, via intracellular interactions, or through a combination of both. Drawing on preclinical literature, structural modeling, and in silico docking, I propose that BPC-157 adopts a polyproline II helix that engages the Src homology 3 (SH3) domains of Src family kinases (SFKs; c-Src, Yes, Fyn). This interaction relieves SH3 domain-mediated autoinhibition of SFKs, resulting in focal adhesion kinase (FAK)-extracellular signal-regulated kinase (ERK) and phosphoinositide 3-kinase (PI3K)-protein kinase B (Akt) signaling cascades. To enable future experimental validation, a custom baculovirus encoding an engineered mCherry-BPC157 2 fusion protein was generated and used to transduce
Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from human gastric juice with regenerative and cytoprotective effects reported across diverse tissues. Despite extensive preclinical study, the precise molecular mechanism underlying BPC-157's pleiotropic pro-repair effects remains incompletely understood. A key unresolved question is whether BPC-157 acts through extracellular receptor engagement, via intracellular interactions, or through a combination of both. Drawing on preclinical literature, structural modeling, and in silico docking, I propose that BPC-157 adopts a polyproline II helix that engages the Src homology 3 (SH3) domains of Src family kinases (SFKs; c-Src, Yes, Fyn). This interaction relieves SH3 domain-mediated autoinhibition of SFKs, resulting in focal adhesion kinase (FAK)-extracellular signal-regulated kinase (ERK) and phosphoinositide 3-kinase (PI3K)-protein kinase B (Akt) signaling cascades. To enable future experimental validation, a custom baculovirus encoding an engineered mCherry-BPC157 2 fusion protein was generated and used to transduce Sf9 cells. Expression of mCherry-BPC157 2 was validated by fluorescent imaging and confirmed by western blot at the expected molecular weight (~31 kDa). Collectively, this work proposes a novel structural and functional mechanism for BPC-157, provides in silico docking support, and introduces a molecular tool to probe the BPC-157 interactome.
","authors":["SCHLOSSER SK."],"year":2025,"journal":"PPR","source":"PPR","preprint":true},{"pmid":"","doi":"10.20944/preprints202512.1011.v3","title":"Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance","abstract":"Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel \"gray market\" of unapproved compounds has emerged, operating largely outside regulatory oversight. Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (Anti-Obesity Drug 9604), BPC-157 (Body Protection Compound 157), CJC-1295, FS-344 (Follistatin-344), GHK-Cu (Glycyl-L-histidyl-L-lysine copper), ipamorelin, MOTS-C (Mitochondrial ORF of the 12S rRNA type-c), sermorelin, SS-31 (Elamipretide), tesamorelin (Egrifta), Tβ4 (thymosin beta-4), and TB-500 (thymosin beta-4 fragment). Many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data is scarce, and there is potential for serious harm to patients. This narrative review focuses on the utilization of peptides in sports medicine, and alternative treatments that may be considered. We provide a framework to navigate patient discussions about peptides to better facilitate evidence-based practices for musculoskeletal healing and athletic performance. We also discuss the placebo effect as a mediator of peptide efficacy, and how social media amplifies this effect.","authors":["Mendias CL","Awan TM."],"year":2026,"journal":"PPR","source":"PPR","preprint":true}],"preprints":[{"pmid":"","doi":"10.21203/rs.3.rs-8167242/v2","title":"BPC-157 Binding to SH3 Domains and Activation of Src Family Kinases: In Silico Modeling and Fluorescent Fusion Protein Production","abstract":" Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from human gastric juice with regenerative and cytoprotective effects reported across diverse tissues. Despite extensive preclinical study, the precise molecular mechanism underlying BPC-157's pleiotropic pro-repair effects remains incompletely understood. A key unresolved question is whether BPC-157 acts through extracellular receptor engagement, via intracellular interactions, or through a combination of both. Drawing on preclinical literature, structural modeling, and in silico docking, I propose that BPC-157 adopts a polyproline II helix that engages the Src homology 3 (SH3) domains of Src family kinases (SFKs; c-Src, Yes, Fyn). This interaction relieves SH3 domain-mediated autoinhibition of SFKs, resulting in focal adhesion kinase (FAK)-extracellular signal-regulated kinase (ERK) and phosphoinositide 3-kinase (PI3K)-protein kinase B (Akt) signaling cascades. To enable future experimental validation, a custom baculovirus encoding an engineered mCherry-BPC157 2 fusion protein was generated and used to transduce
Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from human gastric juice with regenerative and cytoprotective effects reported across diverse tissues. Despite extensive preclinical study, the precise molecular mechanism underlying BPC-157's pleiotropic pro-repair effects remains incompletely understood. A key unresolved question is whether BPC-157 acts through extracellular receptor engagement, via intracellular interactions, or through a combination of both. Drawing on preclinical literature, structural modeling, and in silico docking, I propose that BPC-157 adopts a polyproline II helix that engages the Src homology 3 (SH3) domains of Src family kinases (SFKs; c-Src, Yes, Fyn). This interaction relieves SH3 domain-mediated autoinhibition of SFKs, resulting in focal adhesion kinase (FAK)-extracellular signal-regulated kinase (ERK) and phosphoinositide 3-kinase (PI3K)-protein kinase B (Akt) signaling cascades. To enable future experimental validation, a custom baculovirus encoding an engineered mCherry-BPC157 2 fusion protein was generated and used to transduce Sf9 cells. Expression of mCherry-BPC157 2 was validated by fluorescent imaging and confirmed by western blot at the expected molecular weight (~31 kDa). Collectively, this work proposes a novel structural and functional mechanism for BPC-157, provides in silico docking support, and introduces a molecular tool to probe the BPC-157 interactome.
","authors":["SCHLOSSER SK."],"year":2025,"journal":"PPR","source":"PPR","preprint":true},{"pmid":"","doi":"10.20944/preprints202512.1011.v3","title":"Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance","abstract":"Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel \"gray market\" of unapproved compounds has emerged, operating largely outside regulatory oversight. Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (Anti-Obesity Drug 9604), BPC-157 (Body Protection Compound 157), CJC-1295, FS-344 (Follistatin-344), GHK-Cu (Glycyl-L-histidyl-L-lysine copper), ipamorelin, MOTS-C (Mitochondrial ORF of the 12S rRNA type-c), sermorelin, SS-31 (Elamipretide), tesamorelin (Egrifta), Tβ4 (thymosin beta-4), and TB-500 (thymosin beta-4 fragment). Many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data is scarce, and there is potential for serious harm to patients. This narrative review focuses on the utilization of peptides in sports medicine, and alternative treatments that may be considered. We provide a framework to navigate patient discussions about peptides to better facilitate evidence-based practices for musculoskeletal healing and athletic performance. We also discuss the placebo effect as a mediator of peptide efficacy, and how social media amplifies this effect.","authors":["Mendias CL","Awan TM."],"year":2026,"journal":"PPR","source":"PPR","preprint":true}],"consensus_view":"The literature consensus is that BPC-157 exerts pro-angiogenic effects through VEGFR2 upregulation and activation of the VEGFR2–Akt–eNOS signaling axis, supported by one primary mechanistic study (Hsieh 2017) and corroborated by multiple reviews. However, the precise molecular interaction between BPC-157 and VEGFR2 — particularly whether the C-terminal DDAGLV pharmacophore engages the receptor via electrostatic acidic-mimicry of VEGF-A loop residues or through an alternative contact — has never been experimentally resolved. A competing preprint hypothesis (Schlosser 2025, not peer-reviewed) proposes SH3/Src family kinase engagement as the primary mechanism, which would be VEGFR2-independent. There is no published mutagenesis, charge-reversal, or direct binding affinity data for any BPC-157 analogue against VEGFR2, making this an almost entirely open mechanistic question despite the compound's extensive preclinical study.","knowledge_gaps":"1) No published direct binding affinity measurements (SPR, ITC, fluorescence anisotropy) between BPC-157 or any analogue and the VEGFR2 extracellular domain exist, making it impossible to confirm direct receptor engagement vs. indirect upregulation. 2) No systematic mutagenesis or pharmacophore mapping of the C-terminal DDAGLV motif with respect to VEGFR2 has been reported; whether the tandem DD contributes to binding electrostatically, sterically, or conformationally is unknown. 3) The structural basis of how a 15-residue peptide lacking an obvious RTK-binding domain activates VEGFR2 is not explained; VEGF-A engages VEGFR2 via a large dimeric interface incompatible with simple peptide mimicry. 4) The relative contributions of VEGFR2-dependent vs. SFK/SH3-dependent signaling to BPC-157's angiogenic output have not been deconvolved. 5) No modified analogue of BPC-157 with specific C-terminal charge alterations has been published, making fold #47 and our double-hArg variant genuinely novel chemical entities with no literature precedent.","supporting_evidence":"Hsieh et al. (2017) demonstrated that BPC-157 upregulates VEGFR2 but NOT VEGF-A, strongly suggesting BPC-157 acts at the receptor level through a mechanism distinct from VEGF-A mimicry — consistent with a scaffold-presented contact rather than pure acidic loop mimicry. BPC-157 promoted VEGFR2 internalization via dynamin-dependent endocytosis, a classical RTK activation-induced trafficking event, implying genuine receptor engagement. The fact that BPC-157 consistently outperforms exogenous VEGF in healing models (Seiwerth 2018) suggests it may engage VEGFR2 or its downstream pathways in a complementary or additive way, consistent with a non-competitive binding mode that might tolerate or even benefit from basic residues engaging acidic VEGFR2 surface patches. The VEGFR2 extracellular domain is known to present negatively charged surface patches in the D2-D3 region (the primary VEGF-A binding interface), which could in principle form favorable electrostatic contacts with tandem hArg residues, supporting the 'retained or improved binding via complementary basic engagement' arm of our hypothesis.","challenging_evidence":"1) The Schlosser preprints (2025, not peer-reviewed) propose that BPC-157 acts primarily via intracellular SH3/SFK engagement in a VEGFR2-independent manner, which would imply that C-terminal charge manipulation targeting VEGFR2 engagement is testing the wrong mechanistic node entirely. 2) Hsieh et al. (2017) showed that dynasore (endocytosis inhibitor) blocked VEGFR2 internalization and downstream signaling, but this does not distinguish between BPC-157 directly binding VEGFR2 extracellularly vs. modulating membrane dynamics that secondarily alter VEGFR2 trafficking. 3) VEGF-A engages VEGFR2 through a large protein-protein interface (~900 Ų) involving multiple loops; it is structurally implausible that a 15-residue peptide replicates this interface, raising doubt that acidic-mimicry is the operative mechanism in the first place — which paradoxically may actually support the scaffold-presented contact arm of our hypothesis but makes the acidic-mimicry arm less credible a priori. 4) If downstream signaling (Akt-eNOS, ERK1/2) can be activated through SFK pathways independently of VEGFR2, then even if our double hArg substitution completely ablates VEGFR2 binding, functional angiogenic readouts might not collapse — potentially confounding interpretation of the charge-mimicry hypothesis in cell-based assays unless direct binding is measured orthogonally. 5) All mechanistic data is from preclinical rodent and in vitro human endothelial cell models; no structural data (crystallography, cryo-EM) of BPC-157 bound to VEGFR2 exists to anchor any SAR interpretation."},"caveats":null,"works_cited":[{"pmid_or_doi":"27847966","title":"Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.","year":2017,"relevance":"The only primary research paper in this set directly linking BPC-157 to VEGFR2; demonstrates BPC-157 upregulates VEGFR2 (not VEGF-A), promotes dynamin-dependent VEGFR2 internalization, and activates VEGFR2–Akt–eNOS signaling — directly informing whether BPC-157 engages VEGFR2 in a VEGF-A-mimetic or distinct fashion."},{"pmid_or_doi":"40789979","title":"Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.","year":2025,"relevance":"Independently corroborates VEGFR2 and Akt-eNOS axis as primary angiogenic mechanisms for BPC-157, and notes concurrent ERK1/2 engagement, providing mechanistic context for evaluating how charge-reversal at DD might affect downstream signaling."},{"pmid_or_doi":"10.21203/rs.3.rs-8167242/v2","title":"BPC-157 Binding to SH3 Domains and Activation of Src Family Kinases: In Silico Modeling and Fluorescent Fusion Protein Production","year":2025,"relevance":"Proposes an alternative, VEGFR2-independent mechanism (SH3/SFK engagement) that could sustain downstream signaling even if VEGFR2 direct binding is disrupted by the DD→hArg-hArg substitution, representing a key mechanistic confound for our hypothesis."},{"pmid_or_doi":"10.21203/rs.3.rs-8167242/v1","title":"BPC-157 Predicted to Bind SH3 Domains and Activate Src Family Kinases: In Silico Modeling and Fluorescent Fusion Protein Validation","year":2025,"relevance":"Earlier version of the Schlosser preprint; same mechanistic challenge to VEGFR2-centric models, relevant as a competing hypothesis for BPC-157 signaling mechanism."},{"pmid_or_doi":"29998800","title":"BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.","year":2018,"relevance":"Documents that BPC-157 behaves pharmacologically differently from exogenous VEGF in healing models, supporting the hypothesis that BPC-157's VEGFR2 engagement is mechanistically distinct from canonical VEGF-A acidic loop contact."},{"pmid_or_doi":"34267654","title":"Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.","year":2021,"relevance":"Describes BPC-157's vascular effects including circumvention of vessel occlusion and pro-angiogenic gene expression, providing biological context for interpreting how C-terminal pharmacophore modification might alter in vivo vascular outcomes."},{"pmid_or_doi":"40005999","title":"Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.","year":2025,"relevance":"Comprehensive review of BPC-157 mechanism of action and biological activities; provides regulatory and patent context, noting pleiotropic effects and incomplete mechanistic understanding relevant to interpreting any SAR studies."},{"pmid_or_doi":"30915550","title":"Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.","year":2019,"relevance":"Reviews healing effects across tissue types with reference to growth factor modulation, providing biological benchmark data against which modified peptide variants can be compared."},{"pmid_or_doi":"40756949","title":"Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.","year":2025,"relevance":"Notes VEGFR2 and GH receptor upregulation as key mechanisms; provides systematic evidence quality assessment relevant to interpreting the strength of existing VEGFR2 mechanistic claims."},{"pmid_or_doi":"34380875","title":"Pentadecapeptide BPC 157 and the central nervous system.","year":2022,"relevance":"Documents nitric oxide and Akt pathway involvement in BPC-157 CNS effects, supporting the generality of VEGFR2–Akt–eNOS as a signaling axis and indicating downstream pathway effects that might persist through alternative mechanisms even if direct VEGFR2 engagement is disrupted."},{"pmid_or_doi":"10.20944/preprints202512.1011.v3","title":"Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance","year":2026,"relevance":"Provides regulatory and safety context for BPC-157 as a gray-market peptide; notes absence of rigorous human binding or pharmacokinetic data, underscoring the need for precise SAR studies such as our charge-reversal experiment."},{"pmid_or_doi":"34324435","title":"Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.","year":2021,"relevance":"One of the few human clinical observations with BPC-157; while not mechanistically informative for VEGFR2, establishes in vivo tolerability context relevant to evaluating modified analogs."}]},"onchain":{"hash":null,"signature":null,"data_hash":null,"logged_at":null,"explorer_url":null},"ipfs_hash":null,"created_at":"2026-05-05T03:59:07.577891+00:00","updated_at":"2026-05-05T04:08:41.630600+00:00"}